NervGen Pharma CorpTSXV:NGENView on OTCQX International
- LAST PRICE2.0900
- TODAY'S CHANGE (%)0.0700 (3.4653%)
- Bid / Lots2.0800/ 55
- Ask / Lots2.1100/ 5
- Open / Previous Close2.0500 / 2.0200
- Day Range
- 52 Week Range
- Volume31,400
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NGEN |
|---|---|---|
| 09:41 ET | 500 | 2.05 |
| 09:43 ET | 500 | 2.07 |
| 10:01 ET | 500 | 2.09 |
| 10:30 ET | 1100 | 2.08 |
| 10:32 ET | 6400 | 2.04 |
| 10:44 ET | 100 | 2.06 |
| 10:46 ET | 900 | 2.07 |
| 11:00 ET | 5100 | 2.1 |
| 11:02 ET | 900 | 2.06 |
| 11:06 ET | 100 | 2.06 |
| 11:09 ET | 6200 | 2.09 |
| 11:15 ET | 600 | 2.08 |
| 11:31 ET | 500 | 2.08 |
| 12:07 ET | 2300 | 2.08 |
| 01:19 ET | 1000 | 2.06 |
| 01:26 ET | 4200 | 2.08 |
| 01:28 ET | 500 | 2.09 |
Yesterday
NervGen Engages Russo Partners LLC to Provide Public Relations Services, from 8:32AM ET on Thursday Apr 25, 2024 by Dow Jones
8:32AM ET on Thursday Apr 25, 2024 by Dow Jones
Apr 17, 2024
NervGen Pharma Reports 2023 Year-End Financial Results and Operational Updates, from 9:02AM ET on Wednesday Apr 17, 2024 by Dow Jones
9:02AM ET on Wednesday Apr 17, 2024 by Dow Jones
Mar 28, 2024
NervGen Completes $23 Million Bought Deal Financing, from 9:02AM ET on Thursday Mar 28, 2024 by Dow Jones
9:02AM ET on Thursday Mar 28, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
NervGen Pharma Corp | 140.8M | -5.5x | --- |
Alpha Cognition Inc | 101.9M | -3.4x | --- |
Zentek Ltd | 145.7M | -12.4x | --- |
Medicenna Therapeutics Corp | 135.8M | -11.3x | --- |
Arch Biopartners Inc | 127.0M | -60.9x | --- |
Oncolytics Biotech Inc | 112.4M | -3.6x | --- |
Company Information
NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in discovery, development and commercialization of pharmaceutical products for the treatment of nervous system damage due to injury or disease. The Company is advancing its lead compound, NVG-291, for the treatment of spinal cord injury (SCI), Alzheimer’s disease (AD) and multiple sclerosis (MS). Its NVG-291 is a therapeutic peptide, which is a mimetic of the intracellular domain of protein tyrosine phosphatase, a cell surface receptor known to interact with chondroitin sulfate proteoglycans (CSPGs) and to be involved in the regulation of neuroplasticity and central nervous system repair. The Company has two wholly owned subsidiaries, including NervGen US Inc. and NervGen Australia Pty Ltd.
Contact Information
- Headquarters
- 112-970 Burrard Street, Unit 1290VANCOUVER, BC, Canada V6Z 2R4
- Phone
- 778-731-1711
- Fax
- 604-722-5361
Executives
- Executive Chairman of the Board, Co-Founder
- William Radvak
- President, Chief Executive Officer
- Mike Kelly
- Chief Financial Officer, Company Secretary
- William Adams
- Chief Medical Officer
- Daniel Mikol
- Lead Independent Director
- Glenn Ives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $140.8M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 69.9M |
NervGen Pharma Corp does not pay a dividend. | |
Beta | 1.47 |
EPS | $-0.38 |
Book Value | $-0.03 |
P/E Ratio | -5.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
